文献速递病毒性肝炎艾滋病与性传播感染

HIV合并感染对丙型肝炎病毒感染患者持续病毒学应答后死亡率无影响

No Impact of HIV Coinfection on Mortality in Patients With Hepatitis C Virus Infection After Sustained Virological Response.
PubMed 文献 · Clin Infect Dis · 2025-01-01

这项西班牙前瞻性多中心队列研究纳入1118例治疗前肝硬度≥9.5 kPa且获得持续病毒学应答的丙型肝炎病毒感染者,其中676例(60.5%)合并HIV感染。中位随访76个月后,HIV合并感染与较短生存期无关(风险比0.98,95%CI 0.61-1.58,P=0.939)。

要点

  • 在丙型肝炎病毒慢性感染且晚期纤维化患者中,持续病毒学应答后HIV合并感染不降低总体生存率。
  • 中位随访76个月,HCV单感染死亡46例(10%),HIV/HCV合并感染死亡74例(11%)。
  • 多变量分析中HIV合并感染与较短生存期无关(风险比0.98,95%CI 0.61-1.58,P=0.939)。

核心结论

  • 在丙型肝炎病毒慢性感染且晚期纤维化患者中,HIV合并感染不降低持续病毒学应答后的总体生存率。

研究设计与样本

  • 西班牙前瞻性多中心队列研究,纳入治疗前肝硬度≥9.5 kPa、基于直接抗病毒药物方案获得持续病毒学应答且持续病毒学应答时有肝硬度测量的HIV/HCV合并感染者和HCV单感染者,共1118例,其中676例(60.5%)合并HIV感染。
  • 主要结局为总体生存率,同时评估肝病相关死亡和非肝脏原因死亡。

主要发现

  • 中位随访(Q1-Q3)为76(57-83)个月,持续病毒学应答后HCV单感染组死亡46例(10%),HIV/HCV合并感染组死亡74例(11%)。
  • 总体死亡率为1.9(95%CI 1.6-2.2)/100人年,HCV单感染组为1.9(95%CI 1.4-2.5)/100人年,HIV感染者组为1.8(95%CI 1.6-2.3)/100人年。
  • 多变量分析中,HIV合并感染与较短生存期无关(风险比0.98,95%CI 0.61-1.58,P=0.939)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients with hepatitis C virus (HCV) chronic infection and advanced liver disease, the impact of human immunodeficiency virus (HIV) coinfection on the clinical outcome after sustained virological response (SVR) has not been sufficiently clarified. The aim of this study was to compare the mortality after SVR of patients bearing HCV chronic infection and advanced liver fibrosis, with and without HIV coinfection after a prolonged follow-up. METHODS: This was a prospective multicenter cohort study including individuals with HIV/HCV coinfection and patients with HCV monoinfection from Spain, fulfilling (1) liver stiffness (LS) ≥9.5 kPa before treatment, (2) SVR with a direct-acting antiviral-based regimen, and (3) LS measurement available at SVR. The main outcome was overall survival. Mortality attributable to liver disease and nonhepatic causes was also assessed. RESULTS: A total of 1118 patients were included, of whom 676 (60.5%) had HIV. The median (Q1-Q3) follow-up was 76 (57-83) months. After SVR, 46 (10%) HCV-monoinfected and 74 (11%) HIV/HCV-coinfected patients died. The overall mortality rate (95% CI) was 1.9 (1.6-2.2) per 100 person-years, 1.9 (1.4-2.5) per 100 person-years in patients with HCV monoinfection, and 1.8 (1.6-2.3) per 100 person-years in people with HIV. In the multivariable analysis, HIV coinfection was not associated with shorter survival (hazard ratio, .98; 95% CI, .61-1.58; P = .939). CONCLUSIONS: In patients with HCV chronic infection and advanced fibrosis, HIV coinfection does not reduce the overall survival after SVR. CLINICAL TRIALS REGISTRATION: Clinicaltrials.gov (NCT04460157).

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Martín-Carmona J, Corma-Gómez A, Téllez F, et al. No Impact of HIV Coinfection on Mortality in Patients With Hepatitis C Virus Infection After Sustained Virological Response. Clin Infect Dis. 2025. PMID: 39293030. doi:10.1093/cid/ciae473

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。